ATE140733T1 - Stoffgemische zur anwendung in einem verfahren zur behandlung eines an multipler sklerose leidenden menschen - Google Patents

Stoffgemische zur anwendung in einem verfahren zur behandlung eines an multipler sklerose leidenden menschen

Info

Publication number
ATE140733T1
ATE140733T1 AT91909565T AT91909565T ATE140733T1 AT E140733 T1 ATE140733 T1 AT E140733T1 AT 91909565 T AT91909565 T AT 91909565T AT 91909565 T AT91909565 T AT 91909565T AT E140733 T1 ATE140733 T1 AT E140733T1
Authority
AT
Austria
Prior art keywords
cell receptors
disease
mixtures
substances
treatment
Prior art date
Application number
AT91909565T
Other languages
English (en)
Inventor
Lawrence Steinman
Jorge Oksenberg
Claude Bernard
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24059000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE140733(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE140733T1 publication Critical patent/ATE140733T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT91909565T 1990-05-01 1991-05-01 Stoffgemische zur anwendung in einem verfahren zur behandlung eines an multipler sklerose leidenden menschen ATE140733T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51724590A 1990-05-01 1990-05-01

Publications (1)

Publication Number Publication Date
ATE140733T1 true ATE140733T1 (de) 1996-08-15

Family

ID=24059000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909565T ATE140733T1 (de) 1990-05-01 1991-05-01 Stoffgemische zur anwendung in einem verfahren zur behandlung eines an multipler sklerose leidenden menschen

Country Status (10)

Country Link
EP (2) EP0725277A3 (de)
JP (1) JPH05506995A (de)
AT (1) ATE140733T1 (de)
AU (2) AU653527B2 (de)
CA (1) CA2081672A1 (de)
DE (1) DE69121099T3 (de)
DK (1) DK0527199T4 (de)
ES (1) ES2090335T3 (de)
GR (1) GR3021421T3 (de)
WO (1) WO1991017268A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667967A (en) * 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US6464978B1 (en) * 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
WO1993022455A1 (fr) * 1992-04-30 1993-11-11 Taisho Pharmaceutical Co., Ltd. Procede de detection d'un gene recepteur d'antigene de lymphocytes t
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
AU2950195A (en) * 1994-07-01 1996-01-25 Connective Therapeutics Inc. Methods for diagnosing an immune-related disease and choosing an immune-related therapy
DE19629095A1 (de) * 1996-07-18 1998-02-12 Ralf Dr Gold Verwendung von rekombinantem Myelinprotein zur Behandlung von T-Zell vermittelten Autoimmunerkrankungen des peripheren Nervensystems
NO972556D0 (no) * 1997-06-05 1997-06-05 Forskningsparken I Aas As Metode for merking av væsker og objekter
WO1999015696A1 (en) * 1997-09-19 1999-04-01 Medelys Laboratories Inc. Method and kit for early diagnosis of autoimmunity and lymphoma in central nervous system
EP1517995A4 (de) * 2002-07-03 2007-07-11 Inst Scient Res Inc Zusammensetzungen und verfahren zum nachweis der expression von genen der variablen menschlichen t-zellrezeptor-familie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874845A (en) * 1984-06-13 1989-10-17 Massachusetts Institute Of Technology T lymphocyte receptor subunit
US4886743A (en) † 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
EP0203403B1 (de) * 1985-05-01 1992-10-28 Asahi Kasei Kogyo Kabushiki Kaisha Zum Erkennen von Tumoren fähige klonierte T-Zelle und ein T-Zellen-Antigenrezeptor
US6194561B1 (en) * 1986-03-13 2001-02-27 Roche Molecular Systems, Inc. Characterization and detection of sequences associated with autoimmune diseases
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection
CA1305912C (en) * 1987-06-22 1992-08-04 Richard J. Albertini Detection of lymphocyte amplification
FI891226L (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
DK0552142T3 (da) † 1989-07-19 1998-09-07 Connetics Corp T-cellereceptorpeptider og terapeutika til autoimmune og maligne sygdomme
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
EP0527199A1 (de) 1993-02-17
EP0527199B1 (de) 1996-07-24
WO1991017268A1 (en) 1991-11-14
EP0725277A3 (de) 1996-12-04
DE69121099T3 (de) 2001-01-25
AU7872991A (en) 1991-11-27
CA2081672A1 (en) 1991-11-02
AU685540B2 (en) 1998-01-22
DK0527199T4 (da) 2000-12-04
AU653527B2 (en) 1994-10-06
GR3021421T3 (en) 1997-01-31
DE69121099T2 (de) 1996-12-12
DE69121099D1 (de) 1996-08-29
JPH05506995A (ja) 1993-10-14
DK0527199T3 (da) 1996-10-14
ES2090335T3 (es) 1996-10-16
EP0725277A2 (de) 1996-08-07
AU1004695A (en) 1995-03-16
EP0527199B2 (de) 2000-08-30
EP0527199A4 (en) 1993-03-03

Similar Documents

Publication Publication Date Title
Lauria et al. Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations
DE69121099D1 (de) Stoffgemische zur Anwendung in einem Verfahren zur Behandlung eines an multipler Sklerose leidenden Menschen
BG102265A (bg) Метод и състав за лечение на имунологични заболявания
EP0669001B1 (de) Bestimmung von peptidmotiven auf mhc-molekülen
ATE210721T1 (de) Verwendung eines mbp peptides zur herstellung eines medikamentes für die behandlung von multipler sclerose
DE69726426D1 (de) Unterdrückung von immunantwort durch hemmung von cathepsin s
DE59912716D1 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
EP1003552A4 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGENE ZUR HEMMUNG VON T-ZELL AKTIVIERUNG UND WACHSTUM
BR9506377A (pt) Peptídeo compreendendo uma subsequéncia de gp-39 hc proteina gp-39 hc ou peptideos composição farmacéutica uso da proteina gp-39 hc ou um ou mais dos peptídeos composição de diagnostico e processo de diagnóstico e kit de teste para a detecção de céçiças t auto-reativas ativadas
Byun et al. Bone marrow-derived mesenchymal stem cells prevent alopecia areata development through the inhibition of NKG2D expression: A pilot study.
ATE275968T1 (de) Mitteln zur behandlung von auto-immun krankheiten
PT1025849E (pt) Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
DE69031563D1 (de) Behandlung der autoimmunen uveoretinitis in menschen
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
DE69505376D1 (de) Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
Manjunath et al. Efficacy of various materials in recording enamel rod endings on tooth surface for personal identification
Victorio-Estrada et al. Excessive drinking situations in German alcoholics: replication of a three-factor model used for North Americans
Vences et al. Further investigations on Discoglossus bioacoustics
Turner et al. A new species of Arthroleptella Hewitt, 1926 (Anura: Ranidae) from the Groot Winterhoek Mountains of the Western Cape Province, South Africa
Grant et al. A new species of Leucostethus (Anura, Dendrobatidae) from Gorgona Island, Colombia. ZooKeys 1057: 185–208
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties